Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) will release its earnings data after the market closes on Wednesday, May 1st. Analysts expect Accuray to post earnings of ($0.01) per share for the quarter. Accuray has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Accuray had a negative net margin of 3.25% and a negative return on equity of 28.11%. The firm had revenue of $107.24 million during the quarter, compared to analyst estimates of $107.11 million. During the same period in the previous year, the company earned ($0.02) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

NASDAQ:ARAY opened at $2.22 on Wednesday. Accuray has a one year low of $2.10 and a one year high of $4.30. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.84 and a current ratio of 1.58. The firm has a market cap of $220.16 million, a price-to-earnings ratio of -14.80 and a beta of 1.44. The firm’s fifty day moving average is $2.53 and its two-hundred day moving average is $2.66.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ARAY shares. TheStreet lowered shares of Accuray from a “c-” rating to a “d+” rating in a report on Wednesday, February 14th. Roth Capital reaffirmed a “buy” rating on shares of Accuray in a report on Tuesday, February 13th. Finally, Roth Mkm started coverage on shares of Accuray in a report on Tuesday, February 13th. They issued a “buy” rating and a $9.00 price target on the stock. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.